Search research articles
Contact Us
Filters
Showing results (91-100 of 98) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 98 results.
JAMA Oncology
|
August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
Peter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
The Lancet. Oncology
|
September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.
The New England Journal of Medicine
|
October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
Bradley J Monk, Christine Parkinson, Myong Cheol Lim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 98) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 98 results.
JAMA Oncology
|
August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
Peter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
The Lancet. Oncology
|
September 22, 2020
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A Ascierto, Michele Del Vecchio, Mario Mandalá, et al.
The New England Journal of Medicine
|
October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.
The New England Journal of Medicine
|
September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
James Larkin, Michele Del Vecchio, Mario Mandalá, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2022
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45)
Bradley J Monk, Christine Parkinson, Myong Cheol Lim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2021
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis G Paz-Ares, Suresh S Ramalingam, Tudor-Eliade Ciuleanu, et al.
Page
of 10